Edition:
United Kingdom

Endocyte Inc (ECYT.OQ)

ECYT.OQ on NASDAQ Stock Exchange Global Select Market

16.50USD
16 Jul 2018
Change (% chg)

$-0.76 (-4.40%)
Prev Close
$17.26
Open
$17.63
Day's High
$17.69
Day's Low
$16.04
Volume
314,677
Avg. Vol
540,961
52-wk High
$17.69
52-wk Low
$1.17

Select another date:

Wed, May 9 2018

BRIEF-Endocyte Reports Q1 Loss Per Share $0.16

* Q1 EARNINGS PER SHARE VIEW $-0.19 -- THOMSON REUTERS I/B/E/S

BRIEF-Endocyte Says Data Presented At AACR Show That EC17 Penetrates Solid Tumors Within Minutes And Is Retained Due To High Affinity For Folate Receptor

* ENDOCYTE INC - DATA PRESENTED AT AACR SHOW THAT EC17 PENETRATES SOLID TUMORS WITHIN MINUTES AND IS RETAINED DUE TO HIGH AFFINITY FOR FOLATE RECEPTOR Source text for Eikon: Further company coverage:

BRIEF-Endocyte Nominates Dawn Svoronos For Election To Its Board

* ENDOCYTE NOMINATES DAWN SVORONOS FOR ELECTION TO ITS BOARD OF DIRECTORS AND ANNOUNCES OTHER BOARD DEVELOPMENTS

BRIEF-Endocyte Says ‍In Connection With Machado's Election, Board Increased Size To 11 Members​

* ENDOCYTE INC SAYS ‍IN CONNECTION WITH MACHADO'S ELECTION, BOARD INCREASED SIZE OF BOARD FROM 10 TO 11 MEMBERS - SEC FILING​ Source text: (http://bit.ly/2FKviW0) Further company coverage:

BRIEF-Endocyte Announces Proposed Public Offering Of Common Stock

* ENDOCYTE ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Endocyte Inc Appoints Patrick Machado To Its Board

* ENDOCYTE APPOINTS PATRICK MACHADO, J.D. TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Endocyte Announces Phase 3 Vision Trial,Provides Update On Corporate Strategy And Reports Q4 And 2017 Financial Results

* ENDOCYTE ANNOUNCES PHASE 3 VISION TRIAL AND PROVIDES UPDATE ON CORPORATE STRATEGY AND REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS

BRIEF-Endocyte And ITM Announce Supply Agreement

* ENDOCYTE AND ITM ANNOUNCE SUPPLY AGREEMENT FOR NO-CARRIER-ADDED LUTETIUM FOR THE PHASE 3 VISION TRIAL

Select another date: